Friday, September 30, 2022

561.316.3330

Biotechnology News Magazine

Camilla Soenderby Appointed to F2G Board of Directors

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Camilla Soenderby has been appointed as a Non-Executive Director to its Board of Directors with immediate effect.

Camilla Soenderby is a seasoned biopharma executive with 20 years of international leadership experience from senior strategic and operational roles spanning C-level, global, regional, and country level for leading biopharma companies in the EU, US and Asia. She has a proven track record of developing and growing businesses and has successfully led worldwide cross functional teams to drive portfolio strategy and commercialisation of therapies to treat rare diseases, oncology and specialty conditions.

Patrick Vink, Chairman of F2G Ltd, said: “On behalf of the whole board I am very pleased to welcome Camilla to F2G. She has an impressive track record in building and commercialising global brands. Her experience complements the management team’s expertise as we advance our lead product, olorofim, towards commercialisation.”

Camila Soenderby, Non-Executive Director of F2G, said: “I am very excited to join F2G and to bring my experience to support the commercialisation of such an important product like olorofim, a first-in-class, oral agent for the treatment of severe fungal infections including invasive pulmonary aspergillosis and Valley Fever. This has enormous potential to treat patients with these rare life-threatening infections and addresses a high unmet medical need.”

Francesco Maria Lavino, CEO of F2G Ltd, added: “Camilla’s experience and successful track record in rare diseases will be invaluable as we look to maximise the potential of olorofim. We are focused on accelerating the development of our lead asset and are targeting an NDA filing in 2022. This is an exciting time for F2G as we drive the business to the next phase of growth.”

Most recently, Camilla was Chief Patient Value & Product Strategy Officer at Takeda, where she led the establishment of a global function (following the acquisition of Shire) that comprised Global Commercial Strategy, Global Market Access & Pricing, Global Commercial Excellence, and Global Patient Advocacy, overseeing a portfolio of global brands with more than USD 12 billion in product sales and a large pipeline working in close partnership with R&D.  Prior to the acquisition, Camilla worked as SVP, Head of Global Product Strategy for Shire, having previously held positions of increasing responsibility at Roche Pharma, Abbott (now AbbVie) and Schering Plough.  Camilla began her career as a management consultant at McKinsey & Co. focused on the biopharmaceutical and medical devices industries.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine